Methods to Make Homogenous Antibody Drug Conjugates

Pharmaceutical Research

Volumn 32, Issue 11, 2015, Pages 3480-3493

  Kline, Toni ^a   Steiner, Alexander R ^a   Penta, Kalyani ^a   Sato, Aaron K ^a   Hallam, Trevor J ^a   Yin, Gang ^a  

^a Sutro Biopharma Inc   (United States)

Author keywords

antibody drug conjugates (ADCs); homogenous conjugates; protein engineering; site specific conjugation; targeted delivery

Indexed keywords

AMINO ACID DERIVATIVE; ANTIBODY DRUG CONJUGATE; CYSTEINE; DRUG ANTIBODY; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SORTASE; SORTASE A; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; MOLECULAR LIBRARY; MONOCLONAL ANTIBODY;

AMINO ACID METABOLISM; ANTIBODY ENGINEERING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL FREE SYSTEM; CYCLOADDITION; DISULFIDE BOND; DRUG CONJUGATION; DRUG EFFICACY; DRUG STABILITY; ENZYME SPECIFICITY; GLYCOSYLATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; SONOGASHIRA REACTION; STAPHYLOCOCCUS AUREUS; STREPTOMYCES; STREPTOVERTICILLIUM MOBARAENSE; SUZUKI REACTION; THERMOSTABILITY; ANIMAL; CHEMISTRY; DRUG DESIGN; MOLECULAR LIBRARY; PHARMACEUTICS; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DESIGN; HUMANS; IMMUNOCONJUGATES; PROTEIN ENGINEERING; SMALL MOLECULE LIBRARIES; TECHNOLOGY, PHARMACEUTICAL;

EID: 84943585335     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1596-8     Document Type: Article

References (95)

1. Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates. Cancer Lett. 2007;255(2):232-40.
2. Chari RVJ. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98-107.
3. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006;5(2):147-59.
4. Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, et al. Antibody-drug conjugates: current status and future directions. Drug Discov Today. 2014;19(7):869-81.
5. Chari RVJ, Miller ML, Widdison WC. Antibody-drug conjugates: An emerging concept in cancer therapy. Angew Chem Int Ed Engl. 2014;53(15):3796-827.
6. Flygare JA, Pillow TH, Aristoff P. Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des. 2013;81(1):113-21.
7. Behrens CR, Liu B. Methods for site-specific drug conjugation to antibodies. mAbs. 2014;6(1):46-53.
8. Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. mAbs. 2014;6(1):34-45.
9. LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011;17(20):6437-47.
10. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;30(7):631-7.
11. Katz J, Janik JE, Younes A. Brentuximab Vedotin (SGN-35). Clin Cancer Res. 2011;17(20):6428-36.
12. Hamblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063-70.
13. Wang L, Amphlett G, Blättler WA, Lambert JM, Zhang W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci. 2005;14(9):2436-46.
14. Shen B-Q, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30(2):184-9.
15. Liu CC, Schultz PG. Adding new chemistries to the genetic code. Annu Rev Biochem. 2010;79:413-44.
16. Liu W, Brock A, Chen S, Chen S, Schultz PG. Genetic incorporation of unnatural amino acids into proteins in mammalian cells. Nat Methods. 2007;4(3):239-44.
17. Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A. 2012;109(40):16101-6.
18. Srinivasan G, James CM, Krzycki JA. Pyrrolysine encoded by UAG in Archaea: charging of a UAG-decoding specialized tRNA. Science. 2002;296(5572):1459-62.
19. Blight SK, Larue RC, Mahapatra A, Longstaff DG, Chang E, Zhao G, et al. Direct charging of tRNA(CUA) with pyrrolysine in vitro and in vivo. Nature. 2004;431(7006):333-5.
20. Mukai T, Kobayashi T, Hino N, Yanagisawa T, Sakamoto K, Yokoyama S. Adding l-lysine derivatives to the genetic code of mammalian cells with engineered pyrrolysyl-tRNA synthetases. Biochem Biophys Res Commun. 2008;371(4):818-22.
21. Polycarpo CR, Herring S, Bérubé A, Wood JL, Söll D, Ambrogelly A. Pyrrolysine analogues as substrates for pyrrolysyl-tRNA synthetase. FEBS Lett. 2006;580(28-29):6695-700.
22. Fekner T, Li X, Lee MM, Chan MK. A Pyrrolysine Analogue for Protein Click Chemistry. Angew Chem. 2009;121(9):1661-3.
23. Grabstein KH, Van BM, Marelli M. Amino acid derivatives. WO2014044873 A1, 2014
24. Hofer T, Skeffington LR, Chapman CM, Rader C. Molecularly defined antibody conjugation through a selenocysteine interface. Biochemistry (Mosc). 2009;48(50):12047-57.
25. Kiick KL, Tirrell DA. Protein Engineering by In Vivo Incorporation of Non-Natural Amino Acids: Control of Incorporation of Methionine Analogues by Methionyl-tRNA Synthetase. Tetrahedron. 2000;56(48):9487-93.
26. Tirrell DA, Kiick KL.Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues, US20120077228 A1. 2012
27. Zawada JF, Yin G, Steiner AR, Yang J, Naresh A, Roy SM, et al. Microscale to manufacturing scale-up of cell-free cytokine production-a new approach for shortening protein production development timelines. Biotechnol Bioeng. 2011;108(7):1570-8.
28. Yin G, Garces ED, Yang J, Zhang J, Tran C, Steiner AR. Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system. 4. 2012(2).
29. Groff D, Armstrong S, Rivers PJ, Zhang J, Yang J, Green E. Engineering toward a bacterial "endoplasmic reticulum" for the rapid expression of immunoglobulin proteins. mAbs. 2014;6(3).
30. Johnson DBF, Xu J, Shen Z, Takimoto JK, Schultz MD, Schmitz RJ, et al. RF1 knockout allows ribosomal incorporation of unnatural amino acids at multiple sites. Nat Chem Biol. 2011;7(11):779-86.
31. Murray CJ, Baliga R. Cell-free translation of peptides and proteins: From high throughput screening to clinical production. Curr Opin Chem Biol. 2013;17(3):420-6.
32. Loscha KV, Herlt AJ, Qi R, Huber T, Ozawa K, Otting G. Multiple-site labeling of proteins with unnatural amino acids. Angew Chem Int Ed Engl. 2012;51(9):2243-6.
33. Sando S, Ogawa A, Nishi T, Hayami M, Aoyama Y. In vitro selection of RNA aptamer against Escherichia coli release factor 1. Bioorg Med Chem Lett. 2007;17(5):1216-20.
34. Agafonov DE, Huang Y, Grote M, Sprinzl M. Efficient suppression of the amber codon in E. coli in vitro translation system. FEBS Lett. 2005;579(10):2156-60.
35. Shimizu Y, Inoue A, Tomari Y, Suzuki T, Yokogawa T, Nishikawa K, et al. Cell-free translation reconstituted with purified components. Nat Biotechnol. 2001;19(8):751-5.
36. Lee KB, Kim H-C, Kim D-M, Kang TJ, Suga H. Comparative evaluation of two cell-free protein synthesis systems derived from Escherichia coli for genetic code reprogramming. J Biotechnol. 2012;164(2):330-5.
37. Hallam TJ, Smider VV. Unnatural amino acids in novel antibody conjugates. Futur Med Chem. 2014;6(11):1309-24.
38. Zimmerman ES, Heibeck TH, Gill A, Li X, Murray CJ, Madlansacay MR, et al. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug Chem. 2014;25(2):351-61.
39. Goto Y, Suga H. Translation Initiation with Initiator tRNA Charged with Exotic Peptides. J Am Chem Soc. 2009;131(14):5040-1.
40. Niwa N, Yamagishi Y, Murakami H, Suga H. A flexizyme that selectively charges amino acids activated by a water-friendly leaving group. Bioorg Med Chem Lett. 2009;19(14):3892-4.
41. Krall N, Scheuermann J, Neri D. Small targeted cytotoxics: Current state and promises from DNA-encoded chemical libraries. Angew Chem Int Ed Engl. 2013;52(5):1384-402.
42. Brabletz T. Abstract SY05-03: microRNAs, EMT, and cancer stem cells. Cancer Res. 2012 Apr 15;72(8 Supplement):SY05-03 - SY05-03.
43. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26(8):925-32.
44. Junutula JR, Bhakta S, Raab H, Ervin KE, Eigenbrot C, Vandlen R, et al. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J Immunol Methods. 2008;332(1-2):41-52.
45. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, et al. SGN-CD33A: A novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122(8):1455-63.
46. Liebscher S, Schöpfel M, Aumüller T, Sharkhuukhen A, Pech A, Höss E, et al. N-terminal protein modification by substrate-activated reverse proteolysis. Angew Chem Int Ed Engl. 2014;53(11):3024-8.
47. Yokoyama K, Nio N, Kikuchi Y. Properties and applications of microbial transglutaminase. Appl Microbiol Biotechnol. 2004;64(4):447-54.
48. Spolaore B, Raboni S, Ramos Molina A, Satwekar A, Damiano N, Fontana A. Local unfolding is required for the site-specific protein modification by transglutaminase. Biochemistry (Mosc). 2012;51(43):8679-89.
49. Jeger S, Zimmermann K, Blanc A, Grünberg J, Honer M, Hunziker P, et al. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew Chem Int Ed Engl. 2010;49(51):9995-7.
50. Strop P, Liu SH, Dorywalska M, Delaria K, Dushin RG, Tran TT, et al. Location matters: Site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 2013;20(2):161-7.
51. Farias SE, Strop P, Delaria K, Galindo Casas M, Dorywalska M, Shelton DL, et al. Mass spectrometric characterization of transglutaminase based site-specific antibody-drug conjugates. Bioconjug Chem. 2014;25(2):240-50.
52. Hudak JE, Barfield RM, de Hart GW, Grob P, Nogales E, Bertozzi CR, et al. Synthesis of heterobifunctional protein fusions using copper-free click chemistry and the aldehyde tag. Angew Chem Int Ed Engl. 2012;51(17):4161-5.
53. Agarwal P, van der Weijden J, Sletten EM, Rabuka D, Bertozzi CR. A Pictet-Spengler ligation for protein chemical modification. Proc Natl Acad Sci. 2013;110(1):46-51.
54. Smith EL, Giddens JP, Iavarone AT, Godula K, Wang L-X, Bertozzi CR. Chemoenzymatic Fc glycosylation via engineered aldehyde tags. Bioconjug Chem. 2014;25(4):788-95.
55. Rabuka D, Rush JS, Dehart GW, Wu P, Bertozzi CR. Site-specific chemical protein conjugation using genetically encoded aldehyde tags. Nat Protoc. 2012;7(6):1052-67.
56. Rashidian M, Dozier JK, Distefano MD. Enzymatic labeling of proteins: Techniques and approaches. Bioconjug Chem. 2013;24(8):1277-94.
57. Mazmanian SK, Liu G, Ton-That H, Schneewind O. Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science. 1999;285(5428):760-3.
58. Tsukiji S, Nagamune T. Sortase-mediated ligation: A gift from Gram-positive bacteria to protein engineering. Chem Biochem Eur J Chem Biol. 2009;10(5):787-98.
59. Madej MP, Coia G, Williams CC, Caine JM, Pearce LA, Attwood R, et al. Engineering of an anti-epidermal growth factor receptor antibody to single chain format and labeling by Sortase A-mediated protein ligation. Biotechnol Bioeng. 2012;109(6):1461-70.
60. Matsumoto T, Takase R, Tanaka T, Fukuda H, Kondo A. Site-specific protein labeling with amine-containing molecules using Lactobacillus plantarum sortase. Biotechnol J. 2012;7(5):642-8.
61. Ta HT, Peter K, Hagemeyer CE. Enzymatic antibody tagging: Toward a universal biocompatible targeting tool. Trends Cardiovasc Med. 2012;22(4):105-11.
62. Williamson DJ, Fascione MA, Webb ME, Turnbull WB. Efficient N-Terminal Labeling of Proteins by Use of Sortase. Angew Chem. 2012;124(37):9511-4.
63. Chen I, Dorr BM, Liu DR. A general strategy for the evolution of bond-forming enzymes using yeast display. Proc Natl Acad Sci U S A. 2011;108(28):11399-404.
64. Möhlmann S, Mahlert C, Greven S, Scholz P, Harrenga A. In vitro sortagging of an antibody fab fragment: Overcoming unproductive reactions of sortase with water and lysine side chains. Chem Biochem Eur J Chem Biol. 2011;12(11):1774-80.
65. Pucciarelli MG, Calvo E, Sabet C, Bierne H, Cossart P, García-del Portillo F. Identification of substrates of the Listeria monocytogenes sortases A and B by a non-gel proteomic analysis. Proteomics. 2005;5(18):4808-17.
66. Chen I, Howarth M, Lin W, Ting AY. Site-specific labeling of cell surface proteins with biophysical probes using biotin ligase. Nat Methods. 2005;2(2):99-104.
67. Fernández-Suárez M, Baruah H, Martínez-Hernández L, Xie KT, Baskin JM, Bertozzi CR, et al. Redirecting lipoic acid ligase for cell surface protein labeling with small-molecule probes. Nat Biotechnol. 2007;25(12):1483-7.
68. Puthenveetil S, Liu DS, White KA, Thompson S, Ting AY. Yeast display evolution of a kinetically efficient 13-amino acid substrate for lipoic acid ligase. J Am Chem Soc. 2009;131(45):16430-8.
69. Uttamapinant C, White KA, Baruah H, Thompson S, Fernández-Suárez M, Puthenveetil S, et al. A fluorophore ligase for site-specific protein labeling inside living cells. Proc Natl Acad Sci U S A. 2010;107(24):10914-9.
70. Liu DS, Loh KH, Lam SS, White KA, Ting AY. Imaging trans-cellular neurexin-neuroligin interactions by enzymatic probe ligation. PLoS ONE. 2013;8(2):e52823.
71. Cohen JD, Zou P, Ting AY. Site-specific protein modification using lipoic acid ligase and bis-aryl hydrazone formation. Chem Biochem Eur J Chem Biol. 2012;13(6):888-94.
72. Liu DS, Tangpeerachaikul A, Selvaraj R, Taylor MT, Fox JM, Ting AY. Diels-Alder Cycloaddition for Fluorophore Targeting to Specific Proteins inside Living Cells. J Am Chem Soc. 2012;134(2):792-5.
73. Möhlmann S, Bringmann P, Greven S, Harrenga A. Site-specific modification of ED-B-targeting antibody using intein-fusion technology. BMC Biotechnol. 2011;11:76.
74. Vila-Perello M, Liu Z, Shah NH, Willis JA, Idoyaga J, Muir TW. Streamlined expressed protein ligation using split inteins. J Am Chem Soc. 2013;135(1):286-92.
75. Li Y-M, Yang M-Y, Huang Y-C, Li Y-T, Chen PR, Liu L. Ligation of expressed protein α-hydrazides via genetic incorporation of an α-hydroxy acid. ACS Chem Biol. 2012;7(6):1015-22.
76. Charalambous A, Andreou M, Antoniades I, Christodoulou N, Skourides PA. In vivo, site-specific, covalent conjugation of quantum dots to proteins via split-intein splicing. Methods Mol Biol Clifton NJ. 2012;906:157-69.
77. Hondal RJ, Nilsson BL, Raines RT. Selenocysteine in native chemical ligation and expressed protein ligation. J Am Chem Soc. 2000;123(21):5140-1.
78. Juillerat A, Gronemeyer T, Keppler A, Gendreizig S, Pick H, Vogel H, et al. Directed evolution of O6-alkylguanine-DNA alkyltransferase for efficient labeling of fusion proteins with small molecules in vivo. Chem Biol. 2003;10(4):313-7.
79. Hussain AF, Kampmeier F, von Felbert V, Merk H-F, Tur MK, Barth S. SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells. Bioconjug Chem. 2011;22(12):2487-95.
80. Badescu G, Bryant P, Bird M, Henseleit K, Swierkosz J, Parekh V, et al. Bridging disulfides for stable and defined antibody drug conjugates. Bioconjug Chem. 2014;25(6):1124-36.
81. Robin MP, Mabire AB, Damborsky JC, Thom ES, Winzer-Serhan UH, Raymond JE, et al. New functional handle for use as a self-reporting contrast and delivery agent in nanomedicine. J Am Chem Soc. 2013;135(25):9518-24.
82. Jackson DY, Ha E. Antibody-drug conjugates and related compounds, compositions, and methods. WO2013085925 A1, 2013.
83. Zhou Q, Stefano JE, Manning C, Kyazike J, Chen B, Gianolio DA, et al. Site-specific antibody-drug conjugation through glycoengineering. Bioconjug Chem. 2014;25(3):510-20.
84. Zhu Z, Ramakrishnan B, Li J, Wang Y, Feng Y, Prabakaran P. Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar. mAbs. 2014;6(5).
85. Hu S, Yin Y. Transglutaminase for Protein Drug Modification: Pegylation and beyond. In: Tao J (Alex), Kazlauskas R, editors. Biocatalysis for Green Chemistry and Chemical Process Development [Internet]. John Wiley & Sons, Inc.; 2011 p. 151-72.
86. Li X, Fang T, Boons GJ. Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions. Angew Chem. 2014;126(28):7307-10.
87. Li N, Lim RKV, Edwardraja S, Lin Q. Copper-free Sonogashira cross-coupling for functionalization of alkyne-encoded proteins in aqueous medium and in bacterial cells. J Am Chem Soc. 2011;133(39):15316-9.
88. Li J, Lin S, Wang J, Jia S, Yang M, Hao Z, et al. Ligand-free palladium-mediated site-specific protein labeling inside gram-negative bacterial pathogens. J Am Chem Soc. 2013;135(19):7330-8.
89. Spicer CD, Davis BG. Palladium-mediated site-selective Suzuki-Miyaura protein modification at genetically encoded aryl halides. Chem Commun Camb Engl. 2011;47(6):1698-700.
90. Lin YA, Chalker JM, Floyd N, Bernardes GJL, Davis BG. Allyl sulfides are privileged substrates in aqueous cross-metathesis: Application to site-selective protein modification. J Am Chem Soc. 2008;130(30):9642-3.
91. Lin YA, Chalker JM, Davis BG. Olefin cross-metathesis on proteins: Investigation of allylic chalcogen effects and guiding principles in metathesis partner selection. J Am Chem Soc. 2010;132(47):16805-11.
92. Binder JB, Raines RT. Olefin metathesis for chemical biology. Curr Opin Chem Biol. 2008;12(6):767-73.
93. Lin YA, Boutureira O, Lercher L, Bhushan B, Paton RS, Davis BG. Rapid cross-metathesis for reversible protein modifications via chemical access to Se-allyl-selenocysteine in proteins. J Am Chem Soc. 2013;135(33):12156-9.
94. Molander GA, Raushel J, Ellis NM. Synthesis of an acyltrifluoroborate and its fusion with azides to form amides. J Org Chem. 2010;75(12):4304-6.
95. Noda H, Eros G, Bode JW. Rapid ligations with equimolar reactants in water with the potassium acyltrifluoroborate (KAT) amide formation. J Am Chem Soc. 2014;136(15):5611-4.